Fairvalue-Calculator Fairvalue-Calculator
EN DE

TSH Biopharm Corporation (8432) Fair Value & Analysis

Healthcare · TW · Market cap 2.0B TWD

Price51.20 TWD
Fair Value89.05 TWD
Upside+73.9%
Quality80/100
Evidence: Medium Range 65.99 TWD – 111.32 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

TSH Biopharm Corporation (8432) currently trades at 51.20 TWD, while our model-based Fair Value estimate is 89.05 TWD — implying the stock looks roughly 73.9% undervalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients; AlphaLiquid 100, a liquid biopsy test designed for patients with advanced solid cancers; AlphaLiquid HRR, AlphaSolid, and AlphaSolid HRR, a tissue biopsy test designed for patients with advanced solid cancers. The company was founded in 2000 and is headquartered in Taipei, Taiwan. TSH Biopharm Corporation Limited operates as a subsidiary of TTY Biopharm Company Limited.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is TSH Biopharm Corporation (8432) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 89.05 TWD versus a price of 51.20 TWD — about +74% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 8432?
Our 21-model fair value for TSH Biopharm Corporation is 89.05 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 51.20 TWD.
What is the quality score of 8432?
TSH Biopharm Corporation has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.